Inpharma 1550 - 12 Aug 2006

■ R-GIFOX is a promising salvage regimen forrecurrent or refractory aggressive B-cell non-Hodgkin’slymphoma (NHL), according to preliminary data froma pilot study presented at the International Conferenceon Malignant Lymphoma. Thirteen extensivelypretreated patients received at least three 2-weekcourses of R-GIFOX, comprising IV rituximab375 mg/m2 on day 1 plus IV gemcitabine 1000 mg/m2

on day 2, IV oxaliplatin 130 mg/m2 on day 3 and IVifosfamide 5 g/m2 started on day 3. The overallresponse rate was 77%, with seven completeresponses and three partial responses. Three of the13 patients had died after a median follow-up of6 months. Four of six eligible patients achievedadequate stem cell mobilisation. R-GIFOXdemonstrated a favourable haematological andextrahaematological toxicity profile in this study.Corazzelli G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen forrelapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a pilotstudy. Annals of Oncology 17 (Suppl. 4): 18-24, 2006 801043531

1

Inpharma 12 Aug 2006 No. 15501173-8324/10/1550-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved